Interpace Diagnostics (IDXG) Misses Q1 EPS by 4c, Revenues Miss; Offers FY19 Revenue Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- L3Harris CEO steps down amid conduct review, shares drop
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Reddit leads social media platforms in revenue growth per user
Interpace Diagnostics Reports First Quarter 2019 Financial Results and Provides Business Update
May 13, 2019 4:05 PM EDTQuarterly Revenue Grew to $6.0 Million, a 25% Increase Year-over-Year
Annual 2019 Revenue Guidance of $27 to $28 Million, a 25% Increase
Conference Call and Webcast Monday May 13, 2019 at 4:30 pm ET
Parsippany, NJ, May 13, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG), a fully integrated bioinformatics and commercial molecular diagnostic company, today announced financial results for the first quarter ended March 31, 2019, and reviewed recent business progress.
We had a strong start to the year highlighted by growth and driven by increasing volume in our... More
